Patents Assigned to PGxHealth LLC
-
Patent number: 8129112Abstract: Provided are polynucleotides of molecular variant promoters of the CYP2D6 gene which, for example, are associated with abnormal drug response or individual predisposition to several common diseases and disorders caused by drug under- or over-metabolization, and vectors comprising such polynucleotides. Furthermore, methods of diagnosing the status of disorders related to intermediate metabolization of drugs are described. In addition, kits comprising oligonucleotides hybridizing to the CYP2D6 promoter and/or being capable of being extended into this region useful for diagnosing subjects that are ultrarapid or intermediate metabolizer of drugs are provided.Type: GrantFiled: January 30, 2001Date of Patent: March 6, 2012Assignee: PGxHealth, LLCInventors: Sebastian Raimundo, Ulrich Zanger
-
Patent number: 8039211Abstract: The present invention relates to a polymorphic MRP-1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells.Type: GrantFiled: September 13, 2007Date of Patent: October 18, 2011Assignee: PGxHealth, LLCInventors: Ulrich Brinkmann, Sven Hoffmeyer, Esther Mornhinweg
-
Publication number: 20110091385Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).Type: ApplicationFiled: December 29, 2010Publication date: April 21, 2011Applicant: PGxHealth, LLCInventors: Jayson M. RIEGER, Robert D. THOMPSON
-
Patent number: 7888329Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).Type: GrantFiled: July 13, 2009Date of Patent: February 15, 2011Assignee: PGxHealth, LLCInventors: Jayson M Rieger, Robert D Thompson
-
Patent number: 7884100Abstract: The present invention provides substituted 8-[6-amino-3-pyridyl]xanthines like the compound shown in the following formula: and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: GrantFiled: June 12, 2007Date of Patent: February 8, 2011Assignee: PGxHealth, LLCInventors: Guoquan Wang, Robert D. Thompson, Jayson M. Rieger
-
Patent number: 7871767Abstract: The present invention relates to a polymorphic CYP2C8-polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells.Type: GrantFiled: May 31, 2002Date of Patent: January 18, 2011Assignee: PGxHealth, LLCInventors: Anja Penger, Reimund Sprenger, Ulrich Brinkmann
-
Publication number: 20100273780Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: ApplicationFiled: April 19, 2010Publication date: October 28, 2010Applicant: PGXHEALTH, LLCInventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
-
Publication number: 20100120765Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: ApplicationFiled: July 22, 2009Publication date: May 13, 2010Applicant: PGXHEALTH, LLCInventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
-
Publication number: 20100009366Abstract: The present invention relates to a polymorphic OCT1 polynucleotide. Moreover, the invention relates to genes or vectors comprising the polynucleotides of the invention and to a host cell genetically engineered with the polynucleotide or gene of the invention. Further, the invention relates to methods for producing molecular variant polypeptides or fragments thereof, methods for producing cells capable of expressing a molecular variant polypeptide and to a polypeptide or fragment thereof encoded by the polynucleotide or the gene of the invention or which is obtainable by the method or from the cells produced by the method of the invention. Furthermore, the invention relates to an antibody which binds specifically the polypeptide of the invention. Moreover, the invention relates to a transgenic non-human animal. The invention also relates to a solid support comprising one or a plurality of the above mentioned polynucleotides, genes, vectors, polypeptides, antibodies or host cells.Type: ApplicationFiled: June 3, 2009Publication date: January 14, 2010Applicant: PGXHealth, LLCInventors: Reinhold Kerb, Hermann Koepsell, Ulrich Brinkmann
-
Publication number: 20100004445Abstract: The present invention provides compounds and pharmaceutical compositions that are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents. Also provided are processes for the preparation of the compounds and their intermediates.Type: ApplicationFiled: July 15, 2009Publication date: January 7, 2010Applicant: PGxHealth, LLCInventors: Guoquan Wang, Jayson M. Rieger, Robert Thompson
-
Publication number: 20090280059Abstract: A2A agonists of formula (I) is provided, wherein R1, R2, R4, R5, X, Y, Z, n, p, and q are as described herein. Also provided are compositions comprising and methods of using compounds of formula (I).Type: ApplicationFiled: July 13, 2009Publication date: November 12, 2009Applicant: PGXHEALTH, LLCInventors: Jayson M. Rieger, Robert D. Thompson
-
Patent number: 7579348Abstract: The present invention provides compounds and pharmaceutical compositions that are substituted pyridyl-linked-xantbines of formula I which are selective antagonists of A2B adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: GrantFiled: February 27, 2006Date of Patent: August 25, 2009Assignee: PGxHealth, LLCInventors: Guoquan Wang, Jayson M. Rieger, Robert D. Thompson
-
Publication number: 20090181920Abstract: The present invention relates to a method of treating neuropathic pain via intrathecal administration of agonists of A2A adenosine receptors (ARs).Type: ApplicationFiled: January 9, 2009Publication date: July 16, 2009Applicant: PGXHEALTH, LLCInventors: Linda Watkins, Lisa C. Loram, Mark Hutchinson, Robert D. Thompson, Anthony Beauglehole, Frank W. Schmidtmann, Jayson M. Rieger
-
Publication number: 20090162292Abstract: The present invention provides substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters and pharmaceutical compositions containing the same that are selective agonists of A2A adenosine receptors (ARs). These compounds and compositions are useful as pharmaceutical agents.Type: ApplicationFiled: December 18, 2008Publication date: June 25, 2009Applicant: PGXHEALTH, LLCInventors: Robert D. Thompson, Anthony Beauglehole, Frank Schmidtmann, Jayson M. Rieger
-
Publication number: 20080166723Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.Type: ApplicationFiled: July 26, 2007Publication date: July 10, 2008Applicant: PGxHealth, LLCInventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed
-
Patent number: 7250258Abstract: Haplotypes in the CDK5 gene associated with cognitive response to galantamine treatment are disclosed. Compositions and methods for detecting and using these CDK5 haplotypes in a variety of clinical applications are disclosed. Such applications include articles of manufacture comprising galantamine or derivatives thereof that are approved for treating patients having one of these CDK5 haplotypes, methods and kits for predicting the response of an individual to galantamine based upon his/her haplotype profile, and methods for treating Alzheimer's patients based upon their haplotype profile.Type: GrantFiled: December 7, 2004Date of Patent: July 31, 2007Assignee: PGxHealth LLCInventors: Jeroen Aerssens, Maria Athanasiou, Carlos Brain, Nadine Cohen, Bradley Dain, R. Rex Denton, Richard S. Judson, Vural Ozdemir, Carol R. Reed